Keyword: U.S. Department of Justice
Targeted by the Justice Department in an industrywide copay assistance investigation, Pfizer has now agreed to a $23.85 million deal with the feds.
Newly unsealed court documents allege Insys provided incentives for off-label prescribing of its painkiller Subsys.
Prosecutors said Kris Thorkelson of Manitoba, Canada, admitted to illegal sales of misbranded and counterfeit prescription drugs in the U.S.
Federal prosecutors are close to slapping charges on two drug companies and their executives, Bloomberg reported Tuesday.
A federal judge rebuffed Aegerion's proposed $36M marketing settlement, saying it highlights a "two-tier criminal justice system."
Transparency hasn't made much of a difference when it comes to drug and device makers' payments to doctors, which amounted to $2.6 billion last year.
Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including the French pharma's own Auvi-Q.
A U.S. judge has ordered Novartis to do something it’s been trying for a year to avoid: Hand over documents on 79K events the company says it held with doctors.
J&J has joined fellow drug giant Pfizer and a half-dozen smaller drugmakers in a Justice Department probe of patient-assistance charities.
Add Pfizer to the list of the companies facing a governmental investigation about its ties to copay assistance charities.